Myocardial Damage and Inflammatory Response After Cardiac Surgical Revascularization on Beating and Arrested Heart. [PDF]
Bosnjak A +5 more
europepmc +1 more source
Association Between ECG Findings on Presentation and Outcomes in Patients with Takotsubo Syndrome. [PDF]
Levi-Gofman L +3 more
europepmc +1 more source
Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed +13 more
wiley +1 more source
Variation of pre- and post-race cardiac troponin concentrations in Thoroughbred and Arabian racehorses [PDF]
Nilgün Paksoy +3 more
openalex +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Troponin Elevation Following Anaphylactic Reaction to Multiple Bee Stings in a Previously Healthy Adult. [PDF]
AlSaadi W.
europepmc +1 more source
A quad‐cistronic fluorescent biosensor system for real‐time detection of subcellular Ca2+ signals
Background and Purpose The calcium ion (Ca2+) is a versatile cellular messenger regulating a variety of biological processes. Compounds modulating subcellular Ca2+ signals hold substantial pharmacological potential. Advances in fluorescent biosensors have revolutionised Ca2+ imaging.
Anna Lischnig +7 more
wiley +1 more source
Chemotherapy-related cardiotoxicity: Bridging the gap between evidence and practice. [PDF]
Ali W, Mehmood A, Surani S.
europepmc +1 more source
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev +36 more
wiley +1 more source
Examining the Severity and Consequences of Patients Admitted With Acute Chest Pain via the Acute Physiology and Chronic Health Evaluation II Score and the Relevance of Adding High-Sensitivity Troponin Testing. [PDF]
Farag Y +16 more
europepmc +1 more source

